Crohn's Disease Clinical Trials in Phoenix, Arizona

6 studies are recruiting for crohn's disease in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Elite Clinical Studies /ID# 280477, Phoenix, Arizona

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Arizona Arthritis & Rheumatology Research, PC ( Site 5094), Phoenix, Arizona

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

3. A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

   Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active C…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT05995353 on ClinicalTrials.gov

4. A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

   The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Phoenix Children's Hospital, Phoenix, Arizona

   Locations

   54 in total

   Run by

   Takeda

   See if you can join NCT06100289 on ClinicalTrials.gov

5. A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Phoenix Childrens Hospital, Phoenix, Arizona

   Locations

   54 in total

   Run by

   Takeda

   See if you can join NCT06405087 on ClinicalTrials.gov

6. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

   The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix, Arizona

   Locations

   98 in total

   Run by

   Takeda

   See if you can join NCT05442567 on ClinicalTrials.gov